Article Versions Notes

Deuster E, Hysenaj I, Kahaly M, Schmoeckel E, Mayr D, Beyer S, Kolben T, Hester A, Kraus F, Chelariu-Raicu A, et al. The Platelet-Activating Factor Receptor’s Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine. Cells. 2021; 10(9):2337. https://doi.org/10.3390/cells10092337

Deuster, Eileen, Ivi Hysenaj, Maja Kahaly, Elisa Schmoeckel, Doris Mayr, Susanne Beyer, Thomas Kolben, Anna Hester, Fabian Kraus, Anca Chelariu-Raicu, and et al. 2021. "The Platelet-Activating Factor Receptor’s Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine" Cells 10, no. 9: 2337. https://doi.org/10.3390/cells10092337

Deuster, E., Hysenaj, I., Kahaly, M., Schmoeckel, E., Mayr, D., Beyer, S., Kolben, T., Hester, A., Kraus, F., Chelariu-Raicu, A., Burges, A., Mahner, S., Jeschke, U., Trillsch, F., & Czogalla, B. (2021). The Platelet-Activating Factor Receptor’s Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine. Cells, 10(9), 2337. https://doi.org/10.3390/cells10092337